Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC

Majed A. Refaai, M.D.

Contact Information

Phone Numbers

Office: (585) 276-3927

Fax: (585) 273-3003

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



Dr. Refaai's clinical service is in Transfusion Medicine with subspecialty involvement in laboratory coagulation/thrombosis testing.


Dr. Refaai's recent studies have included: The in-vitro effect of ABO anti-bodies on platelet function; The correlation between cancer and tissue factor (TF) plasma concentrations and its role in developing DVT; The relationship between the circulating TF and the cancer tissue concentrations of TF in different types of mouse models; Beriplex phase IIIb drug study for bleeding patients with Warfarin overdose; Beriplex phase IIIb drug study for surgical patients who require a quick reversal of Warfarin; The effect of ABO non-identical blood products transfusion on platelet function (in-vivo); Platelet transfusion in patients with positive heparin-induced thrombocytopenia; Comparison of tissue factor pathway inhibitor (TFPI) concentration and activity in mononuclear cells from normal individuals versus patients with Paroxysmal Nocturnal Hemoglobinuria; Comparison of TFPI concentrations in normal mouse plasma and endothelial cells versus a diabetic mouse model; Analysis of fatty acid ethyl ester (FAEE) concentrations in binge drinking, chronic alcoholics, and postmortem biopsies.



  • Clinical Pathology/Laboratory Medicine - American Board of Pathology


MD | Aleppo University

Post-doctoral Training & Residency

07/01/2006 - 06/30/2007
Fellowship in Tranfusion Medicine at University of Texas Southwestern

06/30/2003 - 06/30/2006
Residency in Pathology at Barnes-Jewish Hospitals

04/01/1997 - 05/31/2003
Research in at Massachusetts General Hospital

VIEW ALL expand_more

Clinical Trials

Evaluating the Efficacy of the University of Rochester Medical Center's Massive Transfusion Protocol in Trauma Level 1 Patients Utilizing Thromboelastography

Lead Researcher: Majed A Refaai

The purpose of the study is to evaluate the efficacy of the University of Rochester Medical Center's current Massive Transfusion Protocol. Upon arrival of trauma level one designated patients the treating team evaluates the patient's injuries. If the patient is initiated under the facilities Massive Transfusion Protocol and meets other inclusion and exclusion criteria the patient will be enrolled in the study. Study procedures include collection of a blood sample following the transfusion of each shipment, through shipment 5, of blood products outlined in the current Massive Transfusion Protocol. Each blood sample will be run on a Thromboelastograph to evaluate the patient's hematostatic state through resuscitation. One final blood sample will be collected 24 hours following the discontinuation of the Massive Transfusion Protocol and also ran on the thromboelastograph. Due to the critical need for medical intervention, consent procedure will be waived at time of enrollment. An authorized representative for the patient will be identified and approached to obtain consent for use of data collected.

View Study Details


Journal Articles

Refaai MA, Conley GW, Hudson CA, Spinelli SL, Phipps RP, Morrell CN, Blumberg N, McRae HL. "Evaluation of the procoagulant properties of a newly developed platelet modified lysate product." Transfusion.. 2020 May 15; Epub 2020 May 15.

Refaai MA, Shah V, Fernando R. "Performance of the microINR Point-of-Care System: A Multicenter Clinical Trial." Thrombosis and haemostasis.. 2020 Apr 0; 120(4):687-691. Epub 2020 Apr 16.

Boulware R, Refaai MA. "Why do patients with immune thrombocytopenia (ITP) experience lower bleeding events despite thrombocytopenia?" Thrombosis research.. 2020 Jan 15; 187:154-158. Epub 2020 Jan 15.